ArticleArthritis care & research2026
Heterogeneity of Rheumatoid Arthritis-Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural language processing to enhance rheumatoid arthritis care in clinical studies: a scoping review of applications, data, approaches, challenges and future directions.Rheumatology international · 2026Article
- Radiological diversity in rheumatoid arthritis associated with usual interstitial pneumonia (RA-UIP) and its therapeutic implications: towards a generalizable framework of interstitial lung disease treatment.Respiratory research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveWe aimed to identify unique disease trajectories within rheumatoid arthritis-associated interstitial lung disease (RA-ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes.
methodsWe performed a cohort study of RA-ILD within the Veterans Health Administration from 1999 to 2021. Patients with RA-ILD were identified with validated algorithms. Group-based trajectory modeling was used to identify unique groups based on longitudinal FVC values in a primary cohort with baseline and follow-up FVC values and an overall cohort with at least one FVC value. Associations of group assignment with survival and respiratory hospitalization were tested in multivariable Cox regression models adjusting for initial FVC.
resultsWe derived three FVC trajectory groups in the primary cohort (n = 1,092) and eight in the overall cohort (n = 5,172). A total of 82.5% (primary cohort) and 54% (overall cohort) of patients with RA-ILD belonged to progressive groups with FVC percent predicted change ranging from -2.16 to -10.78 (primary) and -0.73 to -1.56 (overall) per year. Relative to the stable group, slow (adjusted hazard ratio [aHR] 1.55 and 1.38) and rapid (aHR 2.07 and 1.77) progressors in the primary cohort had an increased risk of death and respiratory hospitalization, respectively. In the overall cohort, patients with a progressive FVC trajectory also experienced an increased risk of death (aHR range 1.18-2.69) and respiratory hospitalization (aHR range 1.29-2.78).
conclusionUnique disease trajectories based on longitudinal FVC values are independently associated with the risk of death and respiratory-related hospitalization in RA-ILD. Recognition of these unique RA-ILD trajectories could inform management and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.